Literature DB >> 8644648

Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension.

S O de Vries1, W F Heesen, F W Beltman, A H Kroese, J F May, A J Smit, K I Lie.   

Abstract

Although echocardiography provides a reliable method to determine left ventricular (LV) mass, it may not be available in all settings. Numerous electrocardiographic (ECG) criteria for the detection of LV hypertrophy have been developed, but few attempts have been made to predict the LV mass itself from the ECG. In a community-based survey program in the general population, 277 subjects were identified with untreated diastolic hypertension (diastolic blood pressure 95 to 115 mm Hg, 3 occasions) or isolated systolic hypertension (diastolic blood pressure <95 mm Hg and systolic blood pressure 160 to 220 mm Hg, 3 occasions). All subjects underwent ECG and echocardiography on the same day. A multiple linear regression analysis was performed using a random training sample of the data set (n = 185). The independent variables included both ECG and non-ECG variables. The resulting model was used to predict the LV mass in the remainder of the data set, the validation sample (n = 92). Using sex, age, body surface area, the S-voltage in V1 and V4, and the duration of the terminal P in V1 as independent variables, the model explained 45% of the variance (r = 0.67) in the training sample and 42% (r = 0.65) in the validation sample. This result exceeded that of 2 existing ECG models for LV mass (r = 0.40 and 0.41). The correlations between LV mass and combinations of ECG variables used for the detection of LV hypertrophy, such as the Sokolow-Lyon Voltage (r = 0.03) and the Cornell Voltage (r = 0.31), were comparatively low. In settings where echocardiography is not available or is too expensive and time-consuming, prediction of the LV mass from the ECG may offer a valuable alternative.

Entities:  

Mesh:

Year:  1996        PMID: 8644648     DOI: 10.1016/s0002-9149(96)00032-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Acoustic cardiography augments prolonged QRS duration for detecting left ventricular dysfunction.

Authors:  Michel Zuber; Christine H Attenhofer Jost; Peter Kipfer; Sean P Collins; Frank Michota; W Frank Peacock
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-10       Impact factor: 1.468

2.  Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.

Authors:  Takeki Suzuki; Cam Solomon; Nancy Swords Jenny; Russell Tracy; Jeanenne J Nelson; Bruce M Psaty; Curt Furberg; Mary Cushman
Journal:  Circ Heart Fail       Date:  2009-06-19       Impact factor: 8.790

3.  Prediction of Left Ventricular Mass Index Using Electrocardiography in Essential Hypertension - A Multiple Linear Regression Model.

Authors:  Shah Newaz Ahmed; Ratinder Jhaj; Balakrishnan Sadasivam; Rajnish Joshi
Journal:  Med Devices (Auckl)       Date:  2020-06-11

4.  Optimized electrocardiographic criteria for the detection of left ventricular hypertrophy in obesity patients.

Authors:  Sanne M Snelder; Sweder W E van de Poll; Lotte E de Groot-de Laat; Isabella Kardys; Felix Zijlstra; Bas M van Dalen
Journal:  Clin Cardiol       Date:  2020-01-28       Impact factor: 2.882

5.  Electrocardiographic diagnosis of left ventricular hypertrophy in aortic valve disease: evaluation of ECG criteria by cardiovascular magnetic resonance.

Authors:  Stefan Buchner; Kurt Debl; Josef Haimerl; Behrus Djavidani; Florian Poschenrieder; Stefan Feuerbach; Guenter A J Riegger; Andreas Luchner
Journal:  J Cardiovasc Magn Reson       Date:  2009-06-01       Impact factor: 5.364

6.  Development of a nomogram for screening the risk of left ventricular hypertrophy in Chinese hypertensive patients.

Authors:  Chaoyi Ye; Tingjun Wang; Jin Gong; Xiaoqi Cai; Guili Lian; Li Luo; Huajun Wang; Liangdi Xie
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-26       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.